Anti-inflammatory agent 51
Based on 1 Customer Validation
Anti-inflammatory agent 51 (compound 11d) is an amide/sulfonamide derivative with anti-inflammatory activities. Anti-inflammatory agent 51 inhibits NF-κB activation, has the potential for acute lung injury and ulcerative colitis research.
For research use only. We do not sell to patients.
- Purity : 98.08%
- CAS No.: 2911610-03-0
- Formula: C22H22N6O6S
- Molecular Weight:498.51
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| J774.A1 | IC50 |
0.61 μM
Compound: 11d
|
Antiinflammatory activity against mouse J774.A1 cells assessed as inhibition of LPS-induced IL-6 release preincubated with compound for 30 mins followed by LPS-induction and measured after 24 hrs by ELISA analysis
Antiinflammatory activity against mouse J774.A1 cells assessed as inhibition of LPS-induced IL-6 release preincubated with compound for 30 mins followed by LPS-induction and measured after 24 hrs by ELISA analysis
|
[PMID: 37572538] |
| J774.A1 | IC50 |
4.34 μM
Compound: 11d
|
Antiinflammatory activity against mouse J774.A1 cells assessed as inhibition of LPS-induced TNF-alpha release preincubated with compound for 30 mins followed by LPS-induction and measured after 24 hrs by ELISA analysis
Antiinflammatory activity against mouse J774.A1 cells assessed as inhibition of LPS-induced TNF-alpha release preincubated with compound for 30 mins followed by LPS-induction and measured after 24 hrs by ELISA analysis
|
[PMID: 37572538] |
In Vitro
Anti-inflammatory agent 51 (compound 11d) potently reduces the release of IL-6 ( IC50 value of 0.61 μM) and TNF-α (IC50 of 4.34 μM) , and decreased the mRNA level of cytokines in J774A.1 cells. Anti-inflammatory agent 51 restores IκBα and inhibits the translocation of phosphorylated p65 into the nucleus[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2911610-03-0
-
Appearance Solid
-
Molecular Weight 498.51
-
Formula C22H22N6O6S
-
Color Yellow to orange
-
SMILES
O=S(NCC1=CC=CC=N1)(C2=CC=C(C([N+]([O-])=O)=C2)N3CCN(CC3)C4=CC=C(C=C4)[N+]([O-])=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (250.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0060 mL | 10.0299 mL | 20.0598 mL | 50.1494 mL |
| 5 mM | 0.4012 mL | 2.0060 mL | 4.0120 mL | 10.0299 mL | |
| 10 mM | 0.2006 mL | 1.0030 mL | 2.0060 mL | 5.0149 mL | |
| 15 mM | 0.1337 mL | 0.6687 mL | 1.3373 mL | 3.3433 mL | |
| 20 mM | 0.1003 mL | 0.5015 mL | 1.0030 mL | 2.5075 mL | |
| 25 mM | 0.0802 mL | 0.4012 mL | 0.8024 mL | 2.0060 mL | |
| 30 mM | 0.0669 mL | 0.3343 mL | 0.6687 mL | 1.6716 mL | |
| 40 mM | 0.0501 mL | 0.2507 mL | 0.5015 mL | 1.2537 mL | |
| 50 mM | 0.0401 mL | 0.2006 mL | 0.4012 mL | 1.0030 mL | |
| 60 mM | 0.0334 mL | 0.1672 mL | 0.3343 mL | 0.8358 mL | |
| 80 mM | 0.0251 mL | 0.1254 mL | 0.2507 mL | 0.6269 mL | |
| 100 mM | 0.0201 mL | 0.1003 mL | 0.2006 mL | 0.5015 mL |